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AIM OF THE STUDY:
This study compares the analgesic effects of intravenous nalbuphine with intravenous
tramadol on postoperative pain and postoperative analgesic requirement for patients
undergoing percutaneous nephrolithotomy(PCNL).
ABSTRACT:
Post-operative pain produces both acute and chronic effects. Attenuation of this
pain results in attenuation of the stress response, which in turn decreases the
complications and facilitates recovery during the immediate post-operative period.
The usage of nalbuphine and tramadol when administered intraoperatively,
maintains better post-operative hemodynamics , causing excellent post-operative pain
relief. There have been few studies using intravenous nalbuphine and intravenous
tramadol for postoperative analgesia.
In this study, we randomly selected 60 patients and divided them into two
groups. GROUP A  received a bolus dose of Nalbuphine 0.2mg/kg, 30 mins before
extubation and GROUP B received a bolus dose of Tramadol 1mg/kg, 30 mins before
extubation. The primary outcomes measured were  Post-operative visual analog score
and Systolic blood pressure(SBP), diastolic blood pressure(DBP), mean arterial
pressure(MAP), heart rate(HR), respiratory rate(RR) and oxygen saturation(Spo2).
The secondary outcomes measured were Post-operative rescue analgesic initiation
time and Side effects and any other complications.
RESULTS:
The mean visual analog score was less in nalbuphine group when compared to the
tramadol group from 30 minutes to 8 hours time intervals, which was statistically
significant.  The duration of action of both the drugs was about 8 hours as the time to
rescue analgesia was similar in both the groups.
In both the groups , the hemodynamic changes and respiratory parameters in the post
operative period were comparable and statistically insignificant. The nalbuphine group
showed an increased occurrence of drowsiness, while the tramadol group showed an
increased occurrence of nausea and vomiting.
CONCLUSION:
From my study, I conclude that nalbuphine appears to be an effective and safe
analgesic for postoperative pain relief than tramadol in equianalgesic doses, in patients
undergoing percutaneous nephrolithotomy, providing good sedation with minimum
circulatory effects.
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INTRODUCTION 
Nephrolithiasis1 or stone in the kidney is a common problem, whose 
incidence is increasing. The prevalence of nephrolithiasis is 10% in men and 
5% in women. There are many types of kidney stones. Most commonly the 
stones contain calcium. Other types include oxalate, citrate, cysteine stones. 
Non-contrast ct scan is most commonly used for its diagnosis. Patients with 
renal stones usually present with intermittent or continuous severe colicky pain 
in the flank and upper abdomen. 
Conservative non-surgical therapy for small stones consists of 
analgesics (eg. NSAIDS and opiates) and aggressive fluid administration to 
promote urine flow and stone passage. Medical expulsive therapy, which 
promotes ureter relaxation and spontaneous passage involves treatment with 
calcium channel blockers, alpha-blockers and corticosteroids. If the stones are 
resistant to these methods, then surgical intervention is needed. 
Percutaneous nephrolithotomy is generally done for the management of 
large intranephric stones, mainly those resistant to shock wave lithotripsy, 
staghorn calculi and some proximal ureteral stones.Initially a ureteral stent is 
kept in lithotomy and then patient is repositioned to the prone position for the 
percutaneous puncture. General anaesthesia with endotracheal intubation is 
commonly used for this procedure. It allows for a secure airway for positioning 
into the prone position.  
Nalbuphine and Tramadol when administered intravenously 
intraoperatively, tend to maintain better post-operative hemodynamics causing 
excellent post-operative pain relief. Hence the ill effects of post-operative pain 
are prevented by the two drugs.   
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AIM OF THE STUDY 
To compare the analgesic effects of intravenous nalbuphine with 
intravenous tramadol on postoperative pain and postoperative analgesic 
requirement for patients undergoing percutaneous nephrolithotomy” , based on 
 
PRIMARY OUTCOME MEASURES : 
 Post-operative VAS score 
 Systolic blood pressure ,diastolic blood pressure, mean arterial 
pressure, heart rate, respiratory rate and oxygen satuiration were 
measured at baseline and at intervals of 1,5,10,15,30min and 
1,2,3,4,5,6,8,10,12 and 24hours. 
 
SECONDARY OUTCOME MEASURES : 
 Dosage of rescue analgesic requirement 
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PERCUTANEOUS NEPHROLITHOTOMY 
Percutaneous removal of kidney stones – also known as percutaneous 
nephrolithotomy (PCNL) – had been found out around thirty years ago. 
Fernstrom and Johansson (1976)2 first reported the creation of a track for this. 
This technique was then taken up by many other places , mainly by Wickham 
et al (1981) and Alken et al (1981). It has been evolved since then and refined 
with the invention of new endoscopes and various other accessories. 
Percutaneous nephrolithotomy is a procedure used for stone removal 
from the kidney. Percutaneous means ‘through the skin’ and nephrolithotomy 
means ‘taking the stones out of the kidney’. The surgery is done telescopically. 
INDICATIONS : 
 Stones which are bigger than 1.5 cms in the kidneys or the ureter.  
 Stones which are bigger than 1cm occurring in lower pole. 
 Staghorn-- shaped stones. 
 Stones in calyceal diverticulum  
 Stones refractory to other treatments  
  Stones with UPJ obstruction or poor drainage like horseshoe kidney. 
  Patient choice 
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CONTRAINDICATIONS :  
 Absolute contraindications - any active infection, presence of 
coagulopathy, pregnancy, and an unsafe access 
 Relative contraindications – presence of cardiac or pulmonary 
disease, and morbid obesity.  
Anaesthesia and Positioning: 
This surgery should ideally be done under general anaesthesia, since the 
patients have to lie for long duration of time in a relatively uncomfortable 
position, often extending up to three hours. However, it could be done under 
sedo-analgesia if it is done as a staged procedure.  
Percutaneous puncture is the most difficult step. Correct puncture is 
facilitated by the proper positioning , which also protects the anaesthesised 
patient from any injury. The positions which are generally preferred for 
puncture are: 
 Prone-oblique with the affected side tilted upside.  
 completely prone, with the puncture performed from the 
posterolateral direction. 
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PROCEDURE : 
The technique of percutaneous nephrolithotomy consists of three steps: 
1. Puncture of pelvi-calyceal system which is done through the skin, 
2. Development of the track, 
3. Fragmentation and/or removal of the stone. 
General anaesthesia is usually given for PCNL. The patient is initially in 
the supine position. Then the surgeon will perform a cystoscopy and will instill 
x-ray dye or carbon dioxide into the kidney to visualise the branches of the 
collecting system. This helps to identify the stone inside the kidney and for 
accessing the same using guidance. 
The needle tract is then dilated to help in the placement of a plastic 
sheath and telescope to visualize the stone. The stone is then fragmented into 
small pieces using a mechanical, ultrasonic or laser lithotripsy device. It is then 
extracted out through the sheath. Sometimes, removal of all stones may require 
more than one tract to access the stones. A ureteral stent draining the kidney to 
the bladder may be left. Also a nephrostomy tube which drains the kidney will 
be present finally. A urinary catheter will be left in the bladder. An X-ray will 
be done on the following day to look for any residual stone that may be left in 
the kidney. An X-ray dye test is done through the drainage tube from the 
kidney, one or two days post operatively. The tube will be removed if the test is 
satisfactory. The expected hospital stay is for 4 to 5 days.  
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COMPLICATIONS : 
This is relatively a safe procedure, but is associated with the following 
risks and complications. 
 Bleeding: It is usually associated with some blood loss, which rarely 
requires blood transfusions. Autologous blood transfusion technique 
can be used3. 
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 Infection: Its occurrence is minimized by using broad-spectrum 
antibiotics after surgery. 
  Tissue / Organ Injury: Eventhough it is uncommon, injury to bowel, 
liver, spleen, lung, , gallbladder, pancreas and vascular structures can 
occur. Loss of kidney function is a rare but serious risk. The formation 
of scar tissue in the kidney or ureter can occur.  
 Conversion to open surgery: if there is difficulty encountered during 
this procedure. This would result in a bigger incision and a bigger 
recuperation period. 
 Failure to Remove the Stone: Due to the size or location of the stones, 
in which case, additional treatment will be required. 
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PHARMACOLOGY OF TRAMADOL 
ACTIVE INGREDIENT: Tramadol hydrochloride 
CHEMICAL NAME: 2-(dimethylaminomethyl)-1-(3-methoxyphenyl) 
cyclohexanol 
CHEMICAL STRUCTURE: Tramadol exists in four types of configurational 
forms: 
  
(1R,2R)-Tramadol (1S,2S)-Tramadol 
  
(1R,2S)-Tramadol (1S,2R)-Tramadol 
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MECHANISM OF ACTION :  
Tramadol is a centrally acting synthetic opioid analgesic 4,5. The 
mechanisms which appear to be applicable are: 
 Tramadol is a pure agonist (non-selective) at mu, delta and kappa 
opioid receptors with a higher affinity for the mu receptors. 
 Weak inhibition of reuptake of norepinephrine and serotonin and as a 
serotonin releasing agent. 
 It also acts as an 5-HT2C receptor antagonist , NMDA receptor 
antagonist , (α7)5 nicotinic acetlycholine receptor antagonist, and as an 
antagonist at M1 and M3 muscarinic acetylcholine receptors. It is also a 
TRPV1 receptor agonist 
 O-desmethyltramadol, tramadol's major active metabolite is a high-
affinity ligand of δ- and κ-opioid receptors. Its activity at the δ- 
receptor could be involved in its ability to provoke seizures. 
PHARMACOKINETICS:  
1. Tramadol is well absorbed orally. It has a bioavailability of 75%.  
2. Tramadol has a volume of distribution of 306 L after oral administration 
and 203 L after parenteral administration. It has a high tissue affinity. 
3. It is 20% plasma protein bound. 
4. Tramadol is extensively metabolized in the liver by a many pathways, 
including CYP2D6 and CYP3A4, and also by conjugation of parent and 
metabolites. The formation of M1 is dependent upon CYP2D6. N- and 
 11 
 
O- demethylation and glucuronidation or sulfation in the liver are the 
major metabolic pathways. 
5.  Tramadol and its metabolites are excreted primarily in urine. 
6. The plasma half-lives of tramadol and M1 are 6.3 and 7.4 hours 
respectively. Linear pharmacokinetics have been seen following 
multiple doses of tramadol of 50 and 100 mg to steady-state. 
7. A serum concentration of 100 - 300 ng/ml is effective. 
THERAPEUTIC USES :  
It is indicated for treatment of moderate to severe pain in adults and 
adolescents aged > 12 years. 
ROUTES OF ADMINISTRATION : 
Tramadol is given either orally, intramuscularly or by intravenous 
injection(slow) or diluted in solution for administration by infusion or patient 
controlled analgesia. The usual dose is 50mg or 100mg given 4 to 6 hourly by 
either intramuscular or intravenous routes.  
ADVERSE EFFECTS :  
 Very common : nausea and vomiting 
 Common: Feeling drowsy, headache, dry mouth, constipation, sweating 
 Uncommon: palpitations, gastrointestinal irritation and utricaria. 
 Rare: allergic reactions, blurred vision, convulsions, mood changes, 
tremors, urinary problems like difficulty in passing urine or urinary 
retention.  
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When the medicine is stopped, withdrawal symptoms can occur. These 
include hyperactivity, agitation, sleeping disturbances, nervousness, tremors, 
vertigo or gastrointestinal problems. 
CONTRAINDICATIONS: Tramadol is contraindicated in 
 Those having demonstrated hypersensitivity towards tramadol or any of 
the other ingredients.  
 Those with seizure disorder which is not controlled by treatment. 
 Those suffering from acute intoxication with centrally acting 
analgesics, alcohol, opioids, hypnotics or psychotropic drugs. 
 Those who are on MAO inhibitors or within two weeks of their 
withdrawal. 
 narcotic withdrawal treatment. 
INTERACTIONS : 
The following drugs interact with tramadol : 
Antifungal medications ( ketoconazole), Antibiotics (erythromycin and 
linezolid), Antidepressants like monoamine oxidase (MAO) inhibitors 
(phenelzine, isocarboxazid), serotonin norepinephrine reuptake inhibitors 
(SNRIs) (duloxetine and desvenlafaxine), tricyclic antidepressants 
(amitriptyline), and (SSRIs) ( citalopram., fluoxetine), Migraine headache 
drugs (almotripta, frovatriptan), antiepileptics (carbamazepine), Blood thinners 
( warfarin), lithium, digoxin, Quinidine, Rifampin. 
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PHARMACOLOGY OF NALBUPHINE 
ACTIVE INGREDIENT: Nalbuphine Hydrochloride 
CHEMICAL NAME: (–)-17-(cyclobutylmethyl)- 4,5α-epoxymorphinan- 
3,6α,14-triol hydrochloride 
CHEMICAL STRUCTURE: Nalbuphine is a synthetic opioid agonist-antagonist 
analgesic. It belongs to the phenanthrene series. 
 
 
 
SYNTHESIS : 
It is synthesized from oxymorphone, which reacts with cyanogen bromide 
(known as Von Braun reaction), giving rise to a N-cyano derivative. Subsequently, 
hydrolysis of this compound with hydrochloric acid gives rise to 14-
hydroxydihydronormorphone. 
The carbonyl group of 14-hydroxydihydronormorphone is reduced by 
Na hydroxide and then alkylated with cyclobutylmethylbromide, or acylated 
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with cyclobutanecarboxylic acid chloride and then reduction of both the 
carbonyl groups in the compound thus formed using lithium aluminium hydride 
leads to the formation of nalbuphine. 
 
Each milliliter (mL) of Nalbuphine hydrochloride contains 10 mg or 20 
mg of nalbuphine, 0.47 mg of sodium citrate dihydrate and 0.63 mg of citric 
acid, anhydrous which are added as buffers. It may also contain HCl and/or 
NaOH for pH adjustment. pH is 3.7 (3.0 to 4.5). It contains NaCl for 
adjustment of tonicity. 
Multiple-dose vials usually contain methylparaben1.8 mg/mL and 
propylparaben added as preservatives. The single-dose products usually contain 
no bacteriostatic or antimicrobial agent.The portions which are not utilized 
have to be thrown away. 
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MECHANISM OF ACTION :  
Nalbuphine binds to mu, kappa, and delta receptors3: but not to the 
sigma receptors. Nalbuphine hydrochloride is primarily a kappa agonist and 
partial mu antagonist analgesic. It is a potent analgesic and its potency is 
equivalent to that of morphine. It has an opioid antagonist activity of about 1/4 
as potent as nalorphine and 10 times that of pentazocine. 
PHARMACOKINETICS: 
 Nalbuphine has an onset of action within 2 to 3 minutes after 
intravenous administration. It is less than 15 minutes following a 
subcutaneous, or intramuscular injection. 
 The plasma half-life of Nalbuphine is 5 hours.The duration of analgesic 
activity has been found to be from 3 to 6 hours( ≈5 hours). 
 The bioavailability is about 81% (10mg) given intravenously. 
 It is metabolized by the liver and ecreted in the urine. 
THERAPEUTIC USES:  
 Nalbuphine hydrochloride is used for the relief of moderate to severe 
pain.  
 The drug has also been used as a treatment for morphine induced 
pruritus (itching). 
 It can also be used as a supplement for balanced anesthesia. 
 It is also used for preoperative and postoperative analgesia, and for 
obstetrical analgesia during labor and delivery. 
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 The opioid κ-receptor activation antagonizes the various opioid μ-
receptor mediated actions in the brain. 
ROUTES OF ADMINISTRATION :  
It is administered subcutaneously, intramuscularly or intravenously. The 
recommended adult dose is 10 mg for a person weighing seventy kilograms. It 
may be repeated every 3 to 6 hours as necessary. In those who are not tolerant 
to the drug, the recommended single maximum dose is 20 mg. The maximum 
daily dose is 160 mg. The use of nalbuphine as a supplement to balanced 
anesthesia generally requires a larger dose than those recommended for 
analgesia. 
Induction doses of nalbuphine - 0.3 mg/kg to 3 mg/kg iv administered 
over a 10 to 15 minute period along with maintenance doses of 0.25 to 0.5 
mg/kg in single intravenous administarations. 
ADVERSE EFFECTS:  
 Nervous system - sedation (36%), dizziness/vertigo (5%), and headache 
(3%). Nervousness, restlessness, hallucinations, dysphoria, numbness, 
tingling, confusion. 
 Cardiovascular system - hypertension, hypotension, bradycardia, and 
tachycardia. 
 Respiratory - respiratory depression, dyspnea. 
 Gastrointestinal - nausea/vomiting (6%) and dry mouth (4%). Cramps, 
bitter taste and dyspepsia have bben reported rarely. 
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 Dermatologic - itching, burning, and urticaria. 
 Local side effects include pain, redness, swelling, burning sensations at 
the site of injection. 
 Others – hypersensitivity reactions, urinary urgency, blurred vision, 
sweaty/clammy skin. 
CONTRAINDICATIONS : 
 Nalbuphine should not be given to patients who are found to be 
hypersensitive to nalbuphine or to any one of the other ingredients in it. 
 Absolute: pseudomembranous colitis , diarrhea associated with toxins , 
respiratory depression , inflammatory bowel disease, acute asthma and 
sulfite sensitivity. 
 It must be utilised with caution in hepatic or renal impairment, head 
trauma, increased intracranial pressure, morbid obesity and adrenal 
insufficiency. It can produce withdrawal in opioid dependent subjects. 
 Also used with caution in pregnancy – can cause respiratory depression 
at birth, fetal bradycardia, cyanosis and apnea. 
INTERACTIONS : 
 Nalbuphine should not be used along with alvimopan. It increases the 
nalbuphine levels causing an increase in the side effects. It must be 
discontinued 7 days prior to usage of the drug. 
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 The combined use of nalbuphine with fentanyl, alfentanyl, 
buprenorphine and other opioid medications causes an increase in 
sedation and may cause withdrawal symptoms in narcotic addicts. 
 Nalbuphine should not be used with MAO inhibitors like selegiline, 
phenelzine and isocarboxazid and linezolid (antibiotic) because they can 
increase nalbuphine toxicity. Nalbuphine administration must be 
isolated from the administration of MAO inhibitors and linezolid by 
atleast 14 days.  
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ANATOMY OF PAIN 
Acute postoperative pain can induce change in the central nervous 
system, which is known as neuronal plasticity6. This results in sensitization of 
the nervous system, causing allodynia and hyperalgesia. 
“The pain pathway is an afferent three-neuron dual ascending system, 
which receives descending modulation from the cortex, thalamus and 
brainstem. The nociceptors are free nerve endings, which are located in the 
skin, muscle, bone and connective tissue.” 
The first order neurons have their origin in the periphery as either A 
delta or C fibres. 
A delta fibres - transmit first pain (sharp or stinging, well localized pain) 
Polymodal C fibres – transmit second pain ( more diffuse). 
These 1st order neurons synapse with second order neurons in the dorsal 
horn. This synapse occurs primarily within laminas 1,2 and 5. This causes the 
release of neuropeptides and excitatory amino acids. 
The second order neurons are of two types : 
i. Nociceptive specific neurons – located mainly in lamina 1. They 
respond only to painful stimuli. They are mainly associated with sensory 
and discriminative aspects of pain. 
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ii. Wide dynamic range neurons – located in laminae4,5 and 6. They 
respond to both noxious as well as non-noxious stimuli. They are 
concerned with the affective and motivational aspects of pain. 
‘Axons of both these neurons go up in the spinal cord via the dorsal 
column- medial lemniscus and then the anterior lateral spinothalamic tract. 
Then they synapse on 3rd order neurons located in the opposite thalamus. 
From the thalamus, there is projection to the somatosensory cortex, 
where pain is perceived.’ 
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PAIN PROCESSING 
The processing of pain is made up of 4 elements, namely 
 Transduction 
 Transmission 
 Modulation and  
 Perception. 
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1. Transduction : process by which noxious thermal, chemical/ 
mechanical stimuli are converted to an action potential. 
2. Transmission : is the conduction of action potential through the 1st, 2nd, 
3rd order neurons, whose cell bodies lie in dorsal root ganglia, dorsal 
horn and thalamus respectively. 
3. Modulation : refers to altering the afferent neural transmission along 
the pain pathway. It occurs mostly in the dorsal horn of spinal cord. It 
can resulr in either inhibition or augmentation of signals. 
Inhibitory – is by release of GABA and glycine in intrinsic spinal 
neurons. 
Spinal modulation causes augmentation, which is manifested as central 
sensitization. 
Eg . Repetitive C- fibre stimulation of wide dynamic range neurons in 
dorsal horn. 
4. Perception : results from the integration of the painful input into 
somatosensory cortex and limbic cortex. 
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CHEMICAL MEDIATORS OF TRANSDUCTION & 
TRANSMISSION 
The tissue damage following surgical procedures leads to the activation 
of nociceptive nerve endings and local inflammatory cells like macrophages, 
mast cells, lymphocytes etc. Antidromic release of substance P and glutamate 
occurs, which causes vasodilatation, plasma protein extravasation and 
stimulation of cells to release many allogenic substances.  
Eg. Bradykinin, serotonin, histamine, prostaglandins, leukotrienes, cytokines, 
adenosine. 
This will directly produce pain transduction via stimulation of 
nociceptors and also facilitate pain transmission by increasing the excitability 
of nociceptors. 
Peripheral sensitization of C-fibres by these chemicals causes primary 
hyperalgesia – which is the exaggerated response to pain at injury site. 
Dorsal horn of spinal cord has many transmitters and receptors associated with 
pain processing.  
There are three classes of transmitter compounds : 
 Glutamate and aspartate ( excitatory amino acids ) 
 Substance P and neurokinin A ( excitatory neuropeptides ) 
 GABA and glycine ( inhibitory amino acids ) 
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The different types of receptors are as follows :  
 NMDA receptors 
 AMPA receptors 
 Kainate receptors and 
 Metabotropic receptors. 
AMPA and kainite receptors are Na channel dependent. They are 
required for fast synaptic afferent input. NMDA receptors are Ca channel 
dependent. They are activated following prolonged depolarization. 
Substance P removes the magnesium block on the AMPA receptor 
channel, giving glutamate a free entry to NMDA receptors. 
Repetitive C-fibre stimulation of wide dynamic range neurons can lead 
to central sensitization and wind-up. This causes secondary hyperalgesia, 
which is increased pain response evoked by stimuli outside area of injury.  
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EFFECTS OF POSTOPERATIVE PAIN 
Post operative pain produces both acute and chronic effects. 
Attenuation of this pain results in attenuation of the stress response7, 
which in turn decreases the complications and facilitates recovery during the 
immediate post operative period. 
ACUTE EFFECTS : 
Transmission of the pain stimuli to the CNS causes the neuroendocrine 
stress response8. It is a combination of local inflammatory substances like 
cytokines, prostaglandins, leukotrienes etc and systemic mediators.  
It results in increased sympathetic tone. This causes an increased release 
of catecholamines and other catabolic hormones (like cortisol, ACTH, ADH, 
glucagon, aldosterone, renin). The secretion of anabolic hormones is decreased. 
This causes sodium and water retention and increased blood glucose, 
free fatty acids and ketone bodies level. There is also an increase in metabolism 
and oxygen consumption leading to a hypermetabolic, catabolic state.  
The amount of stress response is directly proportional to the degree of 
surgical trauma. 
It can also lead to the development of hypercoagulability, which leads to 
an elevated incidence of deep vein thrombosis, myocardial ischemia, and 
vascular graft failure. 
It can also potentiate immunosuppression. 
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Hyperglycemia may lead onto depression of the immune function and 
poor wound healing.  
Activation of the sympathetic nervous system also causes a delay in the 
return of gastrointestinal motility. This leads to paralytic ileus. 
It can result in increased incidence of oliguria and urinary retention. 
It can also result inanxiety, fear and frustration which leads to poor 
patient satisfaction. 
Spinal reflex inhibition of phrenic nerve activity causes a reduction in 
the pulmonary function postoperatively. In the presence of poorly controlled 
pain, patients tend to take inadequate breaths and have an inadequate cough, 
leading to severe pulmonary complications like atelectasis, pulmonary 
infections etc. 
CHRONIC EFFECTS : 
Chronically occuring postsurgical pain is seen in about 10-65% 
patients9. Few of them have severe chronically occurring postsurgical pain.  
It is mainly due to poorly controlled acute post operative pain. 
This can lead on to long term behavioural and neurobiological changes.  
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PAIN ASSESSMENT METHODS  
Assessment should commence pre-operatively as it can be valuable to 
estimate the patient’s expectation of pain relief. When considering a 
postoperative regimen, it is important to determine any pre-existing chronic 
pain and the use of long term analgesia. Pain assessment should be undertaken 
verbally. Unless the patient’s age and cognitive status makes it impossible, this 
is the principal method10 . These pain assessment methods give numerical 
values which are on a continuous or interval scale. 
The various ways to the measurement of pain consists of  
 verbal and numeric self-rating scales, 
  behavioural observation scales and  
 physiological responses.  
The patient’s self-report provides the most valid measure of the 
experience as pain is subjective. Verbal rating scales (VRS), visual analogue 
scales (VAS) , numerical rating scales (NRS) have been used to measure pain. 
They provide simple, easy, efficient and minimally intrusive measures of pain 
intensity. 
An ideal tool for assessing pain : 
 should be sensitive and free from bias, 
 should be absolute ; rather than relative scales, 
 must give accurate and reliable information, 
 it should distinguish between pain, unpleasantness and emotion, 
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 it must assess experimental and clinical pain, 
 it must estimate confidence of predictions. 
VERBAL RATING SCALES : 
The verbal rating scales consist of a list of adjectives describing the 
different levels of pain intensity. It includes adjectives that reflect the extremes 
of pain ; from 'no pain' to 'extremely intense pain'. It must also have describing 
words to measure gradations of pain intensity. The patients are asked to select 
the phrase that best tells their level of pain. The commonly used scale is a 4 
point scale. no pain = 0, mild pain = 1, moderate pain = 2 or severe pain = 3. 
VRSs are usually valid, easy to administer, score and comprehend. They are 
related significantly and positively to other measures of pain intensity. 
NUMERICAL RATING SCALES : 
The patient is asked to rate the pain from 0 to 10 or from 0 to 100. They 
only provide a verbal response which is then documented. 
NRS are valid, easy to administer and score. It also demonstrates 
positive and significant correlations with other measures of pain intensity. It 
can be used in the elderly and in those with motor problems. The only 
drawback is that it assesses only pain intensity. 
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VISUAL ANALOG SCALE :  
The visual analog score used for pain is a unidimensional measure of 
pain intensity. It is a continuous scale which comprises of a horizontal or a 
vertical line11. It is usually 10 centimeters or (100 mm) in length. The visual 
analog scale is a single-item scale. For the measurement of pain intensity, the 
scale is anchored by “no pain” (which is a score of 0) and “worst imaginable 
pain”(which is a score of 100). It is self- completed by the respondent. Using a 
scale, the score is determined by measuring the distance in (mm) on the 10-cm 
line. A higher score indicates a greater pain intensity. It provides a simple, very 
efficient and non-invasive method for pain measurement. 
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REVIEW OF LITERATURE 
 Minai et al 2003 
The aim of this randomized study was to correlate the analgesic effects 
of Morphine and Nalbuphine in patients undergoing total abdominal 
hysterectomies12.  
Fifty patients were part of the study. All the patients were given 7.5 mg 
of Midazolam orally as premedication. 
Group A were given Morphine 0.1 mg/kg and Group B were given 
Nalbuphine 0.2 mg/kg. Anaesthesia was induced with Thiopentone 4mg/kg and 
0.1 mg/kg Pancuronium was given for muscle relaxation. N2O : O2 – 66% : 
33% and Halothane 0.5- 1% was used for maintenance. If signs of insufficient 
analgesia were present, supplemental doses of the study drug were given. The 
analgesic requirements and side effects were noted. The verbal category scale 
was used for assessing postoperative analgesia requirement.  
Hemodynamic variables showed no significant difference between the 
groups. 4 of them required intraoperative analgesic supplements in the 
Nalbuphine group while it was 12 in the Morphine group. 5 of them in 
Morphine group had pain at reversal while none had pain in Nalbuphine group. 
The interval between the last intraoperative and the 1st postoperative dose was 
greater in the Morphine group. (p < 0.05 ). 5 in Morphine group and only 1 in 
Nalbuphine group had nausea and vomiting.  
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It was concluded that Nalbuphine provided better analgesia and 
hemodynamic stability with a lesser occurrence of nausea and vomitting when 
compared to Morphine. Also, Nalbuphine had a significantly longer duration of 
analgesia. 
 Siddiqui et al 2007  
This study was done to see the analgesic effects of Nalbuphine with 
Tramadol with the total intravenous anaesthesia technique13. In this study, a 
total of seventy patients were studied . All of them were monitored throughout 
the procedure, which consisted of heart rate (HR), non invasive blood pressure 
(B.P), ECG and oxygen saturation. 
Group A - Inj.Tramadol 1.5 mg/kg iv after induction 
Group B - Inj.Nalbuphine 0.1mg/kg iv after induction The patients were 
allowed to breathe spontaneously after the termination of action of 
Succinylcholine.  
There was no statistical significant difference on comparing the 
demographic values. The variables such as systolic (SBP) and Diastolic blood 
pressure(DBP), Mean arterial pressure (MAP), Heart rate and oxygen 
saturation did not show any statistical significance. There was a statistically 
significant difference in the recovery profile. Sedation was more in Tramadol 
group. The pain score was evaluated by using the visual analog score. The 
incidence of pain was more in the Tramadol group.  
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It was concluded from the study that Nalbuphine had an early recovery 
postoperatively with better pain control and hemodynamic stability.  
 Kenan et al 2007 
This study was done to compare the analgesic effects of Tramadol and 
Lornoxicam on postoperative pain in patients, who underwent percutaneous 
nephrolithotomy14.  
Sixty patients were categorized into 3 groups, namely, Tramadol group, 
Lornoxicam group and Normal Saline (NS) group. Tramadol group were given 
100 mg iv ; Lornoxicam group were given 8 mg iv ; and Normal Saline group 
were given 2 ml iv, ten minutes before induction. Anaesthesia was then 
induced with Inj.Fentanyl 1mcg/kg and Thiopentone sodium. Muscle relaxation 
was done with Inj.Vecuronium 0.1 mg/kg. O2: N20 – 50% : 50 % was used 
along with Desflurane 4-6% for maintenance. Mean blood pressure, heart rate, 
SpO2 were recorded before induction and also in the postoperative period.  
Visual analog score, time to first analgesic, and the patient satisfaction 
scores were also documented in the postoperative pereriod. 
 The mean VAS score were significantly low in the Tramadol group (p< 
0.05), when compared to NS group at 15, 30 mins and 1,2,4 hours. It was also 
lower in the Tramadol group at 1 hour after surgery, when compared with 
Lornoxicam group ( p< 0.05). When compared to the Lornoxicam group, the 
time to 1st analgesic was longer in the Tramadol group. (p < 0.05 ). It was 
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concluded that both Tramadol and Lornoxicam were equally effective than 
normal saline, for postoperative pain control.  
The analgesic efficacy of Tramadol was similar to Lornoxicam. At 1 
hour, Tramadol was found to be more effective in patients undergoing 
percutaneous nephrolithotomy. 
 Ouaki et al 2007 
The aim of this trial was to compare the analgesic efficacy of 
intravenous continuous infusion of Nalbuphine and Tramadol given in 
equipotent doses15. The study was done in children aged 1 to 10 years, who 
were to undergo laparoscopic surgery under general anaesthesia. There was 
random allocation of children into two groups. 
Nalbuphine group : ( 0.2 mg/kg, then infusion 0.8 mg/kg/24hrs , and bolus 0.1 
mg/kg). 
Tramadol group : ( 2 mg/kg , then infusion 8 mg/kg/24 hrs and bolus 1 mg/kg). 
The pain score(CHIPPS), respiratory rate, heart rate, SpO2, mean 
arterial pressure, sedation, bolus requirements and side effects were recorded at 
regular intervals. 
CHIPPS, hemodynamic and respiratory parameters were comparable in 
both the groups. The respirstory rate was lower in Nalbuphine group and Spo2 
was lower, although it was not significant(p = 0.06 and 0.09). There was an 
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earlier requirement of a second bolus dose in Tramadol group (p = 0.02). 
Sedation was also found to be less in Tramadol group. (p = 0.01). 
It was concluded that Tramadol appeared to be atleast as efficient as 
Nalbuphine in treating post-operative pain. 
 Van den berg et al 2011 
This study was done to compare the analgesic efficacy and the safety 
profile of Tramadol, Nalbuphine and Pethidine given in equipotent doses with a 
placebo (saline 0.02 ml/kg) given during induction16.  
This study was done in 152 ASA I children and young adults who came 
for adeno-tonsillectomy. Drugs used for premedication (Temazepam and 
Diclofenac), and drugs used for induction(Thiopentone) and maintenance were 
also the same. 
The heart rate (HR) and systolic blood pressure (SBP) were monitored. 
Esmolol,, 2.0 mg/kg intravenously was used for treating any increase in HR or 
SBP >33% of baseline. 
Placebo group required more amount of Esmolol. The Tramadol 
requirement in recovery was reduced (P<0.05). Both Pethidine and Nalbuphine 
caused a significant reduction in the requirement of Esmolol.  
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There was also a decrease in the need for treatment with opioids during 
recovery in the two groups(P<0.005 each). At the end of anesthesia, only 
Pethidine caused a delay in the recovery of spontaneous respiration. The other 
recovery variables were found to be similar. The restlessness–pain scores were 
reduced by all the three drugs.  
It was concluded that Nalbuphine and Pethidine provided better 
analgesia than Tramadol. The safety profile of Nalbuphine and Tramadol was 
found to be more than Pethidine. 
 Shaila et al 2013 
This study was done to evaluate the analgesic effects of intravenous 
Nalbuphine and intravenous Tramadol on postoperative pain17.  
Eighty patients undergoing elective surgery under general anaesthesia 
were randomly divided into two groups of forty each.  
Patients were premedicated with Diazepam 0.15mg/kg orally at night 
before and in the morning. After shifting to the operating room, Midazolam 
0.02mg/kg and Fentanyl 2mcg/kg were given. Patients were induced with 
Propofol 2-2.5mg/kg and muscle relaxation was done with Vecuronium 
0.1mg/kg. O2 : N2O mixture with Isoflurane was given. After the end of 
procedure, they were reversed and extubated. They were allocated into two 
groups.  
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When the pain score was more than three, Group A was given 
Inj.Nalbuphine (0.2mg/kg iv) postoperatively and Group B was given 
Inj.Tramadol ( 1mg/kg iv ) postoperatively. The percentage of pain relief in 
Nalbuphine group was highly significant as compared to Tramadol group at 30 
mins. Mean VAS in Nalbuphine group was 0.72+/-0.64 and mean VAS in 
Tramadol group was 1.72 +/- 0.75 at 30 mins. Pain relief was also significant at 
the end of 1,2, 4, 6, 8 hours.  
Tramadol group had a significant incidence of nausea and vomiting. 
Drowsiness (12.5%) was more in Nalbuphine group when compared to 
Tramadol. 
It was concluded that Nalbuphine appears to be an effective and safe 
analgesic for postoperative pain relief than Tramadol in equianalgesic doses. 
Nalbuphine was found to have minimum circulatory effects, provided good 
sedation and also a lower incidence of nausea and vomiting. They also told that 
its use in the postoperative period can attenuate the mu- opioid related side 
effects, and a ceiling respiratory depression 
 Shiv akshat et al 2014 
This study was done to compare the analgesic efficacy and side effects 
of Nalbuphine and Morphine in patients undergoing gynecological surgeries18. 
VAS score was the primary outcome. Secondary outcomes were the 
requirement of rescue analgesics and side effects. Sixty patients were included 
in this study.  
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Group M (Morphine) and group N (Nalbuphine). Drug solution to be 
used as PCA was prepared by dissolving 20mg Nalbuphine/Morphine in 20 ml 
Normal saline. 
Induction was done with 0.1ml/kg of the solution of unknown opioid 
and a sleep dose of Propofol. Vecuronium 0.1 mg/kg was given for muscle 
relaxation. O2, N2O, Isoflurane were used for maintenance of anaestheisa. 
After extubation, they were shifted to the post-anaesthesia care unit.  
The need for intraoperative analgesia in Nalbuphine group was 
significantly more. The hemodynamic parameters were comparable between 
the two groups in both the intraoperative and the postoperative period. There 
was no significant difference in the occurrence of side effects among the two 
groups. 
It was concluded that both drugs provided similar postoperative 
analgesia with a similar hemodynamic and side effect profile. However, 
Nalbuphine was found to be less effective in the intra-operative period. 
 Ananda et al 2015  
The aim of this prospective- randomized, double-blind study was to 
compare the analgesic efficacy of intravenous Nalbuphine and intravenous 
Morphine in patients undergoing total abdominal hysterectomy19.  
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Duration of analgesia in the post-operative period was the primary 
outcome. Intra-operative hemodynamics and the occurrence of side effects 
were the secondary outcomes. 30 patients were selected. They were randomly 
alloted into 2 groups. All the patients underwent general anaesthesia. After 
shifting inside OT, monitors were connected and peripheral iv line started. 
They were then preoxygenated for 3 mins.  
 
Group N –received inj.Nalbuphine 0.2 mg/kg iv and Group M – 
received inj.Morphine 0.1 mg/kg iv. Induction was done with 2 mg/kg Propofol 
iv and neuromuscular blockade was attained with Inj.Vecuronium 0.1 
mg/kg.patients were maintained with N2O ; O2 – 66% ; 33% and 1MAC 
Isoflurane. 
 
Hemodynamic parameters were monitored intraoperatively every 5 mins 
and in the post-operative period for every 15 mins. The duration of analgesia 
was about 255+/- 43.75 mins in Morphine group and it was 437 +/- 63.87 in 
Nalbuphine group. So there was an early usage of rescue analgesic ( 75 mg of 
Diclofenac) in Morphine group, which was statistically significant (p<0.001).  
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The heart rate was less in Morphine group when compared to 
Nalbuphine group. (p< 0.005). The systolic and diastolic blood pressures were 
also low in Nalbuphine group. Patients in Nalbuphine group were sedated even 
after 30 mins following extubation, when compared to Morphine.  
Hence it was concluded that Nalbuphine is an effective analgesic with 
less circulatory effects, less respiratory depression and produced good sedation. 
 Solanki et al 2015 
The study was to compare the analgesic efficacy of intravenous 
Nalbuphine and Tramadol on postoperative pain in orthopaedic surgeries20. 
Eighty patients, belonging to ASA PS 1 & 2 were studied. 
Premedication was done with Tab.Diazepam 5mg given orally in the 
morning before surgery. The surgery was done under general/ regional 
anaesthesia. Then the patients were assessed for postoperative pain. 
Nalbuphine group – Inj.Nalbuphine 0.15 mg/kg iv 8 hours apart and 
Tramadol group – Inj.Tramadol 2 mg/kg iv 8 hours apart was given. The 
parameters measured were VAS score, BP, PR, RR, SpO2, side effects of drugs 
and the requirement of rescue analgesic.  
The results and observations were derived by applying chi square test 
and students T test. A p value< 0.05 was considered as statistically significant.  
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The Nalbuphine group had significantly higher average sedation scores 
(p <0.0001). Rescue analgesic requirement was more in the Tramadol group. 
Tramadol group had a greater incidence of nausea and vomiting. There was 
some degree of respiratory depression in Nalbuphine group. There was a 
greater amount of hemodynamic stability in Nalbuphine group ( p < 0.005). 
With successive doses, the duration of analgesia became significant and it was 
longer in Nalbuphine group. There was no occurrence of hypotension or 
bradycardia in both the groups. 
It was concluded that Nalbuphine produced better pain relief and 
hemodynamic stability when compared to Tramadol in the post-operative 
period. 
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METHODS 
The study, “A Prospective, randomized study comparing the 
analgesic effects of intravenous nalbuphine with intravenous tramadol on 
postoperative pain and postoperative analgesic requirement for patients 
undergoing percutaneous nephrolithotomy”. was duly submitted before the 
ethical committee of our institution and the ethical committee approval was 
obtained. The study was done on 60 patients coming for percutaneous 
nephrolithotomy, the procedure being done under general anaesthesia. 
 
INCLUSION CRITERIA: 
 Age : 20 -60 years 
 Sex : both 
 Weight : BMI < 30 Kg/m2 
 ASA : I & II 
 Surgery : Elective 
 Mallampatti scores : I & II 
 Who has given valid informed consent. 
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EXCLUSION CRITERIA: 
 Patients not satisfying inclusion criteria. 
 Patients posted for emergency surgery 
 Patients with difficult airway 
 Patients with respiratory or cardiac disease 
 Lack of written informed consent 
 H/O seizures and any neurological deficit or on psychotropic drugs 
 H/O tolerance, dependence or allergy to opioids 
 H/O chronic alcohol consumption 
 Patients with diminished mental competence, deafness and visual 
disturbances. 
The patients who satisfied the inclusion criteria were explained about 
the nature of procedure, tests, advantages and side effects in an elaborate 
manner. A written informed consent was then obtained from the patients. Then 
they were assessed and investigated. Age, height, weight, body mass index of 
the patients were noted down. Various vital parameters like blood pressure, 
heart rate, respiratory rate, oxygen saturation were also noted. Investigations 
included a complete blood count, blood sugar, urea, creatinine, bleeding time, 
clotting time, liver function tests, ecg and chest x-ray. Then examination of the 
various systems and airway assessment was done. Explanation about the visual 
analog score (VAS) was given to all patients. They were told that 0 represented 
“no pain” and 10 represented “ worst possible pain” on the grading scale. 
  
 44 
 
MATERIALS 
DRUGS : 
 Inj. Glycopyrrolate 
 Inj.Fentanyl 
 Inj.Thiopentone sodium 
 Inj,Atracurium 
 Inj.Neostigmine 
 Inj.Nalbuphine 
 Inj.Tramadol 
 All the emergency drugs were kept ready. 
INTRAVENOUS FLUIDS : 
 Normal saline (NS) 
 Ringer lactate (RL) 
MONITORS :  
 NIBP 
 ECG 
 SpO2 
 EtCO2 
 Temperature 
 Urine output  
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The patient was shifted into the operating room. Monitors like non-
invasive blood pressure, ECG, pulse oximetry were connected. The baseline 
vitals like the diastolic and systolic blood pressure, heart rate, SpO2 were 
recorded. Then an intravenous access with a 18G intravenous cannula was 
obtained. Premedication was done with inj.glycopyrrolate 0.2 mg and 
inj.fentanyl 2mcg/kg. The patient was then preoxygenated with a 100 % O2 for 
5 minutes. Induction was done with inj.Thiopentone and muscle relaxation was 
obtained with inj.Atracurium. The patient was then ventilated with a N2O : O2 
in the ratio of 50% : 50% along with desflurane 6% for a time interval of 3 
minutes. Endotracheal intubation was then done with the cuffed endotracheal 
tube of appropriate size. Maintenance of anaesthesia was attained with N2O 
:O2 in the ratio of 50 % : 50 % along with desflurane 3 -6%. 
Towards the end of the surgery the patients were randomized into 2 
groups,  
GROUP A( Nalbuphine ) : received a bolus dose of 0.2mg/kg 30 mins before 
extubation. 
GROUP B (Tramadol ) : received a bolus dose of 1mg/kg 30 mins before 
extubation. 
After the end of the surgery, reversal was done with inj.glcopyrrolate 
0.01 mg/kg and inj.neostigmine 0.05 mg/kg and extubated after thorough oral 
suctioning. Vitals and visual analog score were then monitored immediately 
and also post operatively at regular intervals in the post-operative ward. When 
the vas score was greater than 3, the patients were given rescue analgesic, 
inj.diclofenac 75 mg intramuscularly. 
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PARAMETERS MONITORED 
 
 Age, sex, weight, height, body mass index. 
PRIMARY OUTCOME MEASURES: 
 Post-operative visual analog score and 
 Systolic blood pressure(SBP), diastolic blood pressure(DBP), mean 
arterial pressure(MAP), heart rate(HR), respiratory rate(RR) and 
oxygen saturation(Spo2) were measured at baseline and at intervals 
of 1,5 15,30 mins and 1,2 4,6,8,10 hours postoperatively. 
SECONDARY OUTCOME MEASURES :  
 Post-operative rescue analgesic initiation time 
 Side effects and any other complications. 
The time interval between the administration of the study drug and the 
time when the VAS score becomes greater than 3 is known as the rescue 
analgesic initiation time. Inj.diclofenac im was used as the rescue analgesic.  
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OBSERVATIONS AND ANALYSIS : 
The study is a prospective, randomized study comparing the analgesic 
effects of intravenous nalbuphine with intravenous tramadol on post-operative 
pain and post-operative analgesic requirements for patients undergoing 
percutaneous nephrolithotomy. 
GROUP A (NALBUPHINE) : received a bolus dose of 0.2 mg/kg nalbuphine 
iv, 30 minutes before extubation 
GROUP B (TRAMADOL) : received a bolus dose of 1 mg/kg tramadol iv, 30 
minutes before extubation. 
Descriptive statistics was done for all data and were reported in terms of 
mean values and percentages. Suitable statistical tests of comparison were 
done. Continuous variables were analysed with the unpaired t test. Categorical 
variables were analysed with Fisher Exact Test. Statistical significance was 
taken as P < 0.05. The data was analysed using SPSS version 16 and Microsoft 
Excel 2007. 
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DEMOGRAPHIC PROFILE 
AGE : 
 
 
 
  
Age Distribution Group Nalbuphine % Group Tramadol % 
≤ 30 Years 4 13.33 6 20.00 
31-40 Years 7 23.33 8 26.67 
41-50 Years 13 43.33 10 33.33 
51-60 Years 6 20.00 6 20.00 
Total 30 100 30 100 
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Majority of the Nalbuphine Group patients belonged to the 41-50 Years 
age class interval (n=13, 43.33%) with a mean age of 43.33 years. In the 
Tramadol group patients, majority belonged to the 41-50 years age class 
interval (n=10, 33.33%) with a mean age of 41.37 years. The association 
between the intervention groups and age distribution is considered to be not 
statistically significant since p > 0.05 as per 2 tail unpaired t test. 
  
Age Distribution Group Nalbuphine Group Tramadol 
N 30 30 
Mean 43.33 41.37 
SD 9.90 10.24 
P value Unpaired t Test 0.452561 
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GENDER : 
The two groups showed the following gender distribution. 
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Gender 
Distribution 
Group 
Nalbuphine % 
Group  
Tramadol % 
P value  
Chi Squared Test 
Female 11 36.67 15 50.00 
0.2974 Male 19 63.33 15 50.00 
Total 30 100 30 100 
 
Majority of the Nalbuphine Group patients belonged to the male gender 
group (n=19, 63.33%). In the Tramadol group patients, there was equal 
distribution among the male gender and female gender groups (n=15, 50%). 
The association between the intervention groups and gender distribution is 
considered to be not statistically significant since p > 0.05 as per chi squared 
test. 
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WEIGHT : 
 
 
 
 
Weight Distribution Group Nalbuphine % Group Tramadol % 
≤ 50 kgs 2 6.67 3 10.00 
51-60 kgs 10 33.33 12 40.00 
61-70 kgs 16 53.33 13 43.33 
71-80 kgs 2 6.67 2 6.67 
Total 30 100 30 100 
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Weight Distribution Group Nalbuphine Group Tramadol 
N 30 30 
Mean 61.63 60.77 
SD 6.65 7.11 
P value Unpaired t Test 0.627669 
 
 
Majority of the Nalbuphine Group patients belonged to the 61-70 kgs 
weight class interval (n=16, 53.33%) with a mean weight of 61.63 kgs. In the 
Tramadol group patients, majority belonged to the 61-70 kgs weight class 
interval (n=13, 43.33%) with a mean weight of 60.77 kgs. The association 
between the intervention groups and weight distribution is considered to be not 
statistically significant since p > 0.05 as per 2 tail unpaired t test. 
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HEIGHT : 
 
 
 
Height Distribution Group Nalbuphine % Group Tramadol % 
≤ 1.50 mts 1 3.33 2 6.67 
1.51-1.60 mts 11 36.67 12 40.00 
1.61-1.70 mts 17 56.67 12 40.00 
> 1.70 mts 1 3.33 4 13.33 
Total 30 100 30 100 
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Height Distribution Group Nalbuphine Group Tramadol 
N 30 30 
Mean 1.61 1.62 
SD 0.07 0.08 
P value Unpaired t Test 0.631409 
 
 
Majority of the Nalbuphine Group patients belonged to the 1.61-1.70 
meters height class interval (n=17, 56.67%) with a mean height of 1.61 meters. 
In the Tramadol group patients, majority belonged to the 1.61-1.70 meters 
height class interval (n=12, 40%) with a mean height of 1.62 meters. The 
association between the intervention groups and height distribution is 
considered to be not statistically significant since p > 0.05 as per 2 tail unpaired 
t test. 
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BODY MASS INDEX : 
 
 
BMI Distribution Group Nalbuphine % Group Tramadol % 
Underweight (≤ 18.49) 0 0.00 0 0.00 
Normal (18.50 to 24.99) 25 83.33 27 90.00 
Overweight (25 to 29.99) 5 16.67 3 10.00 
Obese 0 0.00 0 0.00 
Total 30 100 30 100 
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BMI Distribution Group Nalbuphine Group Tramadol 
N 30 30 
Mean 23.81 23.18 
SD 1.35 1.52 
P value Unpaired t Test 0.09453 
 
 
Majority of the Nalbuphine Group patients belonged to the normal BMI 
class interval (n=25, 83.33%) with a mean BMI of 23.81. In the Tramadol 
group patients, majority belonged to the normal BMI class interval (n=27, 
90%) with a mean BMI of 23.18. The association between the intervention 
groups and BMI distribution is considered to be not statistically significant 
since p > 0.05 as per 2 tail unpaired t test. 
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VITALS : 
HEART RATE  
 
 
Heart Rate Status Baseline PO-10 mins 
PO-15 
mins 
PO-30 
mins 
PO-60 
mins 
Group 
Nalbuphine 
N 30 30 30 30 30 
Mean 77.17 94.43 94.03 89.70 84.20 
SD 8.28 9.46 8.50 7.32 7.12 
Group 
Tramadol 
N 30 30 30 30 30 
Mean 77.07 94.33 94.73 88.50 84.00 
SD 7.41 7.28 6.67 6.85 5.73 
P value Unpaired t Test 0.9609 0.9636 0.7240 0.5148 0.9050 
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Heart Rate Status PO-2 hrs 
PO-3 
hrs 
PO-4 
hrs 
PO-6 
hrs 
PO-8 
hrs 
PO-10 
hrs 
Group 
Nalbuphine 
N 30 30 30 30 30 9 
Mean 80.77 77.87 79.03 78.33 80.30 87.33 
SD 6.56 6.07 5.46 6.33 6.73 4.33 
Group 
Tramadol 
N 30 30 30 30 30 4 
Mean 82.13 80.70 79.90 79.00 80.10 81.75 
SD 5.24 5.21 5.92 6.96 7.05 2.75 
P value Unpaired t Test 0.3766 0.1472 0.2480 0.1293 0.4109 0.0705 
 
 
Majority of the Nalbuphine Group patients had mean heart rate ranging 
from 77.17 bpm at baseline to 87.33 bpm at 10 hours postoperatively. Similarly 
majority of the Tramadol Group patients had mean heart rate ranging from 
77.07 bpm at baseline to 81.75 bpm at 10 hours postoperatively. The 
association between the intervention groups and heart rate is considered to be 
not statistically significant since p > 0.05 as per 2 tail unpaired t test. 
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SYSTOLIC BLOOD PRESSURE : 
 
 
Systolic Blood Pressure 
Status Baseline 
PO-10 
mins 
PO-15 
mins 
PO-30 
mins 
PO-60 
mins 
Group 
Nalbuphine 
N 30 30 30 30 30 
Mean 119.53 127.20 127.10 125.97 120.73 
SD 7.07 7.52 7.09 7.25 5.65 
Group 
Tramadol 
N 30 30 30 30 30 
Mean 120.07 127.17 127.80 126.03 120.50 
SD 6.52 6.24 6.60 6.82 6.14 
P value Unpaired t Test 0.7625 0.9852 0.6937 0.9709 0.8788 
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Systolic Blood Pressure 
Status 
PO-2 
hrs 
PO-3 
hrs 
PO-4 
hrs 
PO-6 
hrs 
PO-8 
hrs 
PO-10 
hrs 
Group 
Nalbuphine 
N 30 30 30 30 30 9 
Mean 114.37 114.20 114.23 116.50 120.07 128.33 
SD 5.26 4.94 5.36 3.94 5.35 5.66 
Group 
Tramadol 
N 30 30 30 30 30 4 
Mean 115.10 113.50 114.27 117.43 122.43 128.50 
SD 5.97 4.90 4.69 4.99 4.25 0.58 
P value Unpaired t Test 0.6158 0.5835 0.9796 0.4246 0.0630 0.9324 
 
 
Majority of the Nalbuphine Group patients had mean systolic blood 
pressure ranging from 114.37 mm Hg at baseline to 128,33 mm Hg at 10 hours 
postoperatively. Similarly majority of the Tramadol Group patients had mean 
systolic blood pressure ranging from 115.10 mm Hg at baseline to 128,50 mm 
Hg at 10 hours postoperatively. The association between the intervention 
groups and systolic blood pressure is considered to be not statistically 
significant since p > 0.05 as per 2 tail unpaired t test. 
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DIASTOLIC BLOOD PRESSURE : 
 
 
Diastolic Blood Pressure 
Status Baseline 
PO-10 
mins 
PO-15 
mins 
PO-30 
mins 
PO-60 
mins 
Group 
Nalbuphine 
N 30 30 30 30 30 
Mean 75.73 84.70 80.47 77.63 74.57 
SD 7.18 7.24 6.34 4.68 4.30 
Group 
Tramadol 
N 30 30 30 30 30 
Mean 75.67 84.37 83.10 78.43 74.70 
SD 6.38 5.35 4.78 4.71 4.98 
P value Unpaired t Test 0.9698 0.8400 0.0748 0.5119 0.9120 
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Diastolic Blood Pressure 
Status 
PO-2 
hrs 
PO-3 
hrs 
PO-4 
hrs 
PO-6 
hrs 
PO-8 
hrs 
PO-10 
hrs 
Group 
Nalbuphine 
N 30 30 30 30 30 9 
Mean 73.40 74.60 74.83 75.67 78.10 82.11 
SD 4.94 4.51 4.91 5.45 6.25 3.14 
Group 
Tramadol 
N 30 30 30 30 30 4 
Mean 74.53 75.37 77.53 79.10 81.57 88.25 
SD 5.32 5.14 5.40 5.04 4.12 2.22 
P value Unpaired t Test 0.3958 0.5416 0.4473 0.3140 0.5144 0.0936 
 
 
Majority of the Nalbuphine Group patients had mean diastolic blood 
pressure ranging from 75.73 mm Hg at baseline to 82.11 mm Hg at 10 hours 
postoperatively. Similarly majority of the Tramadol Group patients had mean 
diastolic blood pressure ranging from 75.67 mm Hg at baseline to 88.25 mm 
Hg at 10 hours postoperatively. The association between the intervention 
groups and diastolic blood pressure is considered to be not statistically 
significant since p > 0.05 as per 2 tail unpaired t test. 
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MEAN ARTERIAL PRESSURE : 
 
 
Mean Arterial Pressure 
Status Baseline 
PO-10 
mins 
PO-15 
mins 
PO-30 
mins 
PO-60 
mins 
Group 
Nalbuphine 
N 30 30 30 30 30 
Mean 90.33 98.93 96.00 93.73 89.97 
SD 6.96 7.06 6.18 4.95 4.43 
Group 
Tramadol 
N 30 30 30 30 30 
Mean 90.43 98.53 98.00 94.30 89.90 
SD 6.35 5.17 5.01 5.17 4.87 
P value Unpaired t Test 0.9538 0.8033 0.1741 0.6662 0.9560 
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Mean Arterial Pressure 
Status 
PO-2 
hrs 
PO-3 
hrs 
PO-4 
hrs 
PO-6 
hrs 
PO-8 
hrs 
PO-10 
hrs 
Group 
Nalbuphine 
N 30 30 30 30 30 9 
Mean 87.03 87.80 88.00 89.23 92.07 97.67 
SD 4.34 3.84 3.57 3.74 4.70 3.61 
Group 
Tramadol 
N 30 30 30 30 30 4 
Mean 88.07 88.17 89.77 91.93 95.13 101.75 
SD 4.64 4.60 4.60 4.59 3.89 1.71 
P value Unpaired t Test 0.3768 0.7387 0.1023 0.3154 0.1180 0.2185 
 
 
Majority of the Nalbuphine Group patients had mean arterial pressure 
ranging from 90.33 mm Hg at baseline to 97.67 mm Hg at 10 hours 
postoperatively. Similarly majority of the Tramadol Group patients had mean 
arterial pressure ranging from 90.43 mm Hg at baseline to 101.75 mm Hg at 10 
hours postoperatively. The association between the intervention groups and 
mean arterial pressure is considered to be not statistically significant since p > 
0.05 as per 2 tail unpaired t test. 
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RESPIRATORY RATE : 
 
 
Respiratory Rate Status Baseline PO-30 mins PO-60 mins PO-2 hrs PO-3 hrs 
Group Nalbuphine 
N 30 30 30 30 30 
Mean 13.00 13.30 12.40 11.93 12.40 
SD 1.20 1.42 0.72 0.74 1.00 
Group Tramadol 
N 30 30 30 30 30 
Mean 13.40 14.33 13.27 12.67 12.70 
SD 1.22 1.71 1.01 0.92 0.84 
P value Unpaired t Test 0.2063 0.1136 0.2564 0.9713 0.2137 
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Respiratory Rate Status PO-4 hrs PO-6 hrs PO-8 hrs PO-10 hrs 
Group Nalbuphine 
N 30 30 30 9 
Mean 12.73 12.83 12.60 14.67 
SD 1.08 0.83 1.61 0.71 
Group Tramadol 
N 30 30 30 4 
Mean 12.67 13.10 12.80 15.25 
SD 1.03 1.06 1.16 0.50 
P value Unpaired t Test 0.8075 0.2841 0.5829 0.1268 
 
Majority of the Nalbuphine Group patients had mean respiratory rate 
ranging from 13 bpm at baseline to 14.67 bpm at 10 hours postoperatively. 
Similarly majority of the Tramadol Group patients had mean respiratory rate 
ranging from 13.40 bpm at baseline to 15.25 bpm at 10 hours postoperatively. 
The association between the intervention groups and respiratory rate is 
considered to be not statistically significant since p > 0.05 as per 2 tail unpaired 
t test. 
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SpO2 :  
 
 
Peripheral Capillary Oxygen 
Saturation Status 
Baseli
ne 
PO-30 
mins 
PO-60 
mins 
PO-2 
hrs 
PO-3 
hrs 
Group Nalbuphine 
N 30 30 30 30 30 
Mean 98.70 98.43 98.67 98.87 98.90 
SD 0.47 0.57 0.48 0.35 0.31 
Group Tramadol 
N 30 30 30 30 30 
Mean 98.73 98.40 98.60 98.77 98.83 
SD 0.45 0.62 0.50 0.43 0.38 
P value Unpaired t Test 0.7790 0.8291 0.5995 0.3253 0.4562 
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Peripheral Capillary Oxygen 
Saturation Status PO-4 hrs PO-6 hrs PO-8 hrs PO-10 hrs 
Group Nalbuphine 
N 30 30 30 9 
Mean 98.90 98.90 98.83 98.78 
SD 0.31 0.31 0.38 0.44 
Group Tramadol 
N 30 30 30 4 
Mean 98.87 98.87 98.80 99.00 
SD 0.35 0.35 0.41 0.00 
P value Unpaired t Test 0.6936 0.6936 0.7438 0.1690 
 
 
Majority of the Nalbuphine Group patients had Peripheral Capillary 
Oxygen Saturation ranging from 98.70 % at baseline to 98.78 % at 10 hours 
postoperatively. Similarly majority of the Tramadol Group patients had mean 
Peripheral Capillary Oxygen Saturation ranging from 98.73 % at baseline to 99 
% at 10 hours postoperatively. The association between the intervention groups 
and Peripheral Capillary Oxygen Saturation is considered to be not statistically 
significant since p > 0.05 as per 2 tail unpaired t test. 
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VISUAL ANALOG SCORE : 
The postoperative pain scores in the two groups, which were analysed 
by the visual analog score, were as follows, 
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Visual Analog Score PO-30 mins 
PO-1 
hrs 
PO-2 
hrs 
PO-4 
hrs 
PO-6 
hrs 
PO-8 
hrs 
PO-10 
hrs 
Group 
Nalbuphine 
N 30 30 30 30 30 30 9 
Mean 1.33 0.33 0.20 0.07 0.57 2.57 3.67 
SD 0.55 0.48 0.41 0.25 0.57 0.73 0.71 
Group 
Tramadol 
N 30 30 30 30 30 30 4 
Mean 1.70 0.40 0.30 0.40 1.00 3.10 3.75 
SD 0.60 0.50 0.47 0.62 0.64 0.61 0.50 
P value Unpaired t 
Test 0.0160 0.0395 0.0197 0.0098 0.0076 0.0032 0.8143 
 
By conventional criteria the association between the intervention groups 
and Visual Analog Score is considered to be statistically significant between 30 
minutes-8 hours since p < 0.05 as per unpaired t test. In simple terms, in 
patients belonging to Nalbuphine intervention group, the mean Visual Analog 
Score is decreased to an average of 0.84 points in comparison with patients 
belonging Tramadol intervention group in whom the mean Visual Analog 
Score is an average of 1.15 points. The mean Visual Analog Score was 
meaningfully less in Nalbuphine intervention group compared to Tramadol 
intervention group by a mean difference of 0.31 points. This significant 
difference of 27% decrease in mean Visual Analog Score in Nalbuphine 
intervention group compared to Tramadol intervention group is true and has 
not occurred by chance. 
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This indicates that there is a true difference among intervention groups 
and the difference is significant with a p-value of 0.0160, 0.0395, 0.0197, 
0.0098, 0.0076 and 0.0032 according to unpaired t-test. In this study we can 
safely conclude that Nalbuphine results in significantly decreased mean Visual 
Analog Score compared to Tramadol when used on postoperative pain and as 
postoperative analgesic for patients undergoing percutaneous nephrolithotomy. 
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RESCUE ANALGESIA INITIATION TIME :  
The time to initiation of rescue analgesic ( inj.diclofenac) in the two 
groups were as follows, 
 
 
Postoperative Rescue 
Analgesia Initiation Time 
Group 
Nalbuphine % 
Group 
Tramadol % 
8 hours 21 70.00 26 86.67 
10 hours 9 30.00 4 13.33 
Total 30 100 30 100 
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Postoperative Rescue Analgesia Initiation Time Group Nalbuphine Group Tramadol 
N 30 30 
Mean 8.60 8.27 
SD 0.93 0.69 
P value Unpaired t Test 0.121609 
 
 
Majority of the Nalbuphine Group patients belonged to the 8 hours 
Postoperative Rescue Analgesia Initiation Time class interval (n=21, 70%) with 
a mean Postoperative Rescue Analgesia Initiation Time of 8.60 hours. In the 
Tramadol group patients, majority belonged to the 8 hours Postoperative 
Rescue Analgesia Initiation Time class interval (n=26, 86,67%) with a mean 
Postoperative Rescue Analgesia Initiation Time of 8.27 hours. The association 
between the intervention groups and Postoperative Rescue Analgesia Initiation 
Time is considered to be not statistically significant since p > 0.05 as per 2 tail 
unpaired t test. 
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SIDE EFFECTS : 
The side effects which occurred in the two groups were as follows, 
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Side Effects Group Nalbuphine % 
Group 
Tramadol % 
P value| 
Fishers Exact Test 
Headache 1 3.33 1 3.33 >0.9999 
Drowsiness 5 16.67 2 6.67 0.4238 
Nausea 2 6.67 5 16.67 0.4238 
Vomiting 0 0.00 5 16.67 0.0522 
 
Majority of the Nalbuphine Group patients had drowsiness as the major 
side effect (n=5, 16.67%). In the Tramadol group patients, majority had nausea 
and vomitting as the major side effect (n=5, 16.67%). The association between 
the intervention groups and side effects is considered to be not statistically 
significant since p > 0.05 as per 2 tail unpaired t test. 
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DISCUSSION : 
There are a number of reasons for the undertreatment of postoperative 
pain. This includes lack of knowledge about the dose ranges, the duration of 
action of drugs, and also the fear of addiction and respiratory depression. 
This prospective, randomized study was done to find a drug, which 
provided good relief of postoperative pain, in this study, we compared 
nalbuphine, an opioid agonist – antagonist with tramadol, which is very 
commonly used for relief of postoperative pain. 
The demographic profile of the patients in the study did not show any 
sifnificant difference. 
The nature of postoperative pain varies from one person to another due 
to factors like age, sex, nature of procedure, psychological makeup of patient.  
All the pain evaluations were made by the same observer. Also, the 
premedication and the anaesthetic techniques used were similar. Equianalgesic 
doses of drugs were used, which was determined by previews and previous 
studies.  
The patients were divided into two groups,  
GROUP A (NALBUPHINE) : they received a bolus dose of 0.2 mg/kg 
nalbuphine iv , 30 minutes before extubation 
GROUP B (TRAMADOL) : they received a bolus dose of 1 mg/kg tramadol iv, 
30 minutes before extubation.  
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At 30 minutes, the percentage of pain relief in nalbuphine group was 
highly significant as compared to tramadol group. Mean VAS in nalbuphine 
group was 1.33 and mean VAS in tramadol group was 1.70 at 30 mins.  
Visual analog score between 30 minutes-8 hours was statistically 
significant since p < 0.05 as per unpaired t test. In other words, in patients 
belonging to Nalbuphine intervention group, the mean Visual Analog Score 
decreased to an average of 0.84 points. In comparison, in patients belonging to 
the Tramadol intervention group, the mean Visual Analog Score is an average 
of 1.15 points. The mean Visual Analog Score was meaningfully less in 
Nalbuphine intervention group when compared to Tramadol intervention group 
by a mean difference of 0.31 points. This significant difference of 27% 
decrease in mean Visual Analog Score in Nalbuphine intervention group when 
compared to Tramadol intervention group has not occurred by chance and 
hence is true. This indicates that there is a true difference among the two 
intervention groups and the difference is significant with a p-value of 0.0160, 
0.0395, 0.0197, 0.0098, 0.0076 and 0.0032 according to unpaired t-
test.(p<0.05). 
The cardiovascular parameters monitored were systolic blood pressure 
(SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP) and heart 
rate (HR). The mean changes in these parameters did not show any statistically 
significant difference between two groups. ( p > 0.05). Siddiqui et al and Ouaki 
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et al also showed that there was no hemodynamic significance between the two 
groups. 
The respiratory parameters which were monitored were respiratory rate 
(RR) and oxygen saturation (SpO2). There was no statistical significance in 
these parameters between the two groups. (p > 0.05). The respiratory 
parameters were also comparable in the study by Shaila et al and Ouaki et al. 
The mean postoperative Rescue Analgesia Initiation Time in nalbuphine 
group was about 8.60 hours. In the Tramadol group, the mean Postoperative 
Rescue Analgesia Initiation Time was 8.27 hours. The association between the 
intervention groups and Postoperative Rescue Analgesia Initiation Time is 
considered not to be statistically significant since p > 0.05 as per 2 tail unpaired 
t test. 
Nalbuphine group showed an increased incidence of drowsiness 
(16.67%) when compared to the tramadol group (6.67). Shaila et al also had an 
increased incidence of drowsiness (12.5%) in the nalbuphine group. However, 
the incidence of nausea and vomiting was more in the tramadol group (16.67%) 
when compared to nalbuphine group, which had nausea (6.67%) and none of 
them had vomiting. This is in concordance with studies by Solanki et al and 
Shaila et al, which had an increased occurrence of nausea and vomiting in 
tramadol group. 
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These findings were similar to the results of Shaila et al , which stated 
that nalbuphine was a safe and effective analgesic for postoperative pain than 
tramadol. 
The safety profile of nalbuphine is been widely accepted by many 
studies such as those by Siddiqui et al, Ouaki et al, Van Den Berg et al, Shaila 
et al and Solanki et al. 
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SUMMARY 
“This study was conducted to compare the analgesic effects of 
intravenous nalbuphine with intravenous tramadol on postoperative pain and 
postoperative analgesic requirement for patients undergoing percutaneous 
nephrolithotomy” 
The following observations were made: 
The mean visual analog score was less in nalbuphine group when 
compared to tramadol group from 30 minutes to 8 hours time intervals, which 
was statistically significant. The duration of action of both the drugs was about 
8 hours as the time to rescue analgesia was similar in both the groups and 
statistically insignificant. 
In both the groups , the hemodynamic changes and respiratory 
parameters in the post operative period were comparable and insignificant. 
The nalbuphine group showed an increased occurrence of drowsiness, 
while tramadol group showed an increased occurrence of nausea and vomiting, 
though there was no statistically significant difference between two groups 
with respect to side effects. 
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CONCLUSION 
It was concluded that nalbuphine appears to be an effective and safe 
analgesic for postoperative pain relief than tramadol in equianalgesic doses, in 
patients undergoing percutaneous nephrolithotomy, providing good sedation 
with minimum circulatory effects. 
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ANNEXURES 
 
  
  
INFORMATION TO PARTICIPANTS 
Investigator: Dr.M.SURESH 
Name of the Participant:  
 Title: 
“A Prospective, randomized study comparing the analgesic effects of intravenous 
nalbuphine with intravenous tramadol on postoperative pain and postoperative analgesic 
requirement for patients undergoing percutaneous nephrolithotomy “ 
You are invited to take part in this research study.We have got approval from the IEC. Your are asked 
to participate because you satisfy the eligibility criteria.We want to compare and study the safety and 
efficacy of intravenous nalbuphine and intravenous tramadol on post operative pain relief in patients 
undergoing elective percutaneous nephrolithotomy. 
What is the Purpose of the Research: 
To compare the analgesic effects of intravenous nalbuphine with intravenous tramadol on 
postoperative pain and postoperative analgesic requirement for patients undergoing percutaneous 
nephrolithotomy, based on 
Post-operative VAS score 
Systolic blood pressure (SBP), diastolic blood pressure (DBP), mean arterial pressure (MAP), 
heart rate (HR), respiratory rate (RR) and oxygen satuiration(Spo2) were measured at baseline 
and at intervals of 1,5,10,15,30min and 1,2,3,4,5,6,8,10,12 and 24hours 
Post operative rescue analgesia requirement 
 
The Study Design: 
60 Patients presenting for elective percutabneous nephrolithotomy were randomly assigned into two 
groups. 
GROUP A( Nalbuphine ) : received a bolus dose of 0.2mg/kg IV 30 mins before extubation 
 
GROUP B (Tramadol ) : received a bolus dose of 1mg/kg IV 30 mins before extubation 
 
.Benefits 
The usage of nalbuphine and tramadol when administered intraoperatively, maintains better post 
operative hemodynamics , causing excellent post operative pain relief. 
Discomforts and risks 
May cause nausea, vomiting, drowsiness, headache, anaphylactic reactions. 
This intervention has been shown to be well tolerated as shown by previous studies.And if you do not 
want to participate you will have alternative of setting the standard treatment and your safety is our 
prime concern. 
All tests, medicine and medical services concerned with this research will be provided free of cost to 
the patient. 
Time and date : 
Place : 
Signature of the Investigator : ____________________________ Signature / Thumb Impression 
of patient  
Name of the Investigator : ____________________________ Patient name : 
  
  
 
PATIENT CONSENT FORM 
Study Title : 
“A Prospective, randomized study comparing the analgesic effects of 
intravenous nalbuphine with intravenous tramadol on postoperative pain and 
postoperative analgesic requirement for patients undergoing percutaneous 
nephrolithotomy” 
Study center:  
Institute of Anaesthesiology and Critical Care, 
Madras Medicalcollege, 
Chennai- 600003. 
 
 
Participant name : Age: Sex: I.P.No: 
 
 
I confirm that I have understood the purpose of the above study . I have the 
opportunity to ask the question and all my questions and doubts have been answered 
to my satisfaction. 
 
 I have been explained about the safety,advantage and disadvantage of the 
drugs. 
 
 I understand that my participation in the study is voluntary and that I am free 
to withdraw at anytime without giving any reason. 
 
 I understand that investigator ,regulatory authorities and the ethical committee 
will not need my permission to look at my health records both in respect to current 
study and any further research that may be conducted in relation to it, even if I 
withdraw from the study . I understand that my identity will not be revealed in any 
information released to third parties or published , unless as required under the law . I 
agree not to restrict the use of any data or results that arise from the study . 
 
Time:  
 
Date: Signature/thumb impression of patient  
 
Place: Patient name: 
 
Signature of the investigator: Name of the investigator: 
  
  
 
 
  
  
 
  
  
PROFORMA 
Date:      Roll no:     
Name:  
Age: Ht:Wt:   Sex:  IP No: 
Diagnosis: 
Surgical procedure: 
PRE OP ASSESSMENT: 
HISTORY: Any Co-morbid illness 
 H/O Documented Difficult Airway 
 H/O previous surgeries 
EXAMINATION : CVS : RS : Hb : 
MEASURES OF STUDY OUTCOME: 
   HR  SBP  DBP  MAP  RR  Spo2  VAS  SCORE 
PRE OP        
INTRA OP( AT THE 
TIME OF DRUG 
ADMINISTRATION) 
       
1 MIN        
5 MIN        
10 MIN        
15 MIN        
30 MIN        
1 HR        
2 HR        
4 HR         
5 HR        
6 HR        
8 HR        
10 HR        
12 HR        
24 HR        
  
 
COMPLICATIONS/ SIDE EFFECTS IN POST OPERATIVE PERIOD: 
RESCUE ANALGESICS USED:
  
 
SERIAL 
NO
NAME
AGE/
SEX
WEIGHT 
(KGS)
HEIGHT
 (METERS)
BMI  
(KG/M2)
SBP 
(mmHg)
DBP
 (mmHg)
MAP 
(mmHg)
HR  
/min
RR /
min
SpO2 % 10 MINS 15 30 60 2 HRS 3 4 6 8 10
1  SUMATHI 38/F 57 1.54 24.03 116 70 85 76 13 99 86 83 77 75 74 77 76 78 82
2 LOGESWARI 37/F 59 1.52 25.53 127 83 98 92 12 99 108 106 94 95 89 82 84 86 92
3 TAMILARASI 45/F 53 1.51 23.24 116 75 89 77 12 99 88 85 84 79 78 80 84 89 86 89
4 ASIRVATHAM 43/M 65 1.65 23.87 118 73 88 73 14 99 93 89 90 86 86 84 80 92 89
5 PARAMASIVAM 45/M 67 1.7 23.18 127 87 100 87 15 98 103 96 98 94 87 90 86 81 83
6 SUNDHARAM 48/M 62 1.65 23.77 121 83 96 84 13 99 84 81 85 76 73 70 74 75 81 84
7 SUBRAMANI 57/M 65 1.64 24.16 130 84 99 87 12 98 99 101 96 89 92 90 86 84 82
8 ARAVIND 38/M 71 1.72 23.99 126 79 95 92 11 99 110 108 104 99 86 88 90 87 86
9 SELVARAJ 57/M 60 1.66 21.77 123 81 95 88 16 98 94 94 92 87 83 76 81 82 92
10 RAJKUMAR 28/M 69 1.7 23.87 112 77 89 69 14 99 87 85 80 77 70 73 77 70 72 83
11 VITLA 40/F 57 1.52 24.67 121 73 89 74 13 99 95 97 90 81 69 72 76 74 77
12 MADURAPANDI 47/M 63 1.65 23.14 117 73 88 77 12 99 83 84 79 73 77 81 83 79 85
13 RAJESHWARI 49/F 58 1.55 24.14 109 68 82 62 13 98 80 82 74 68 70 67 68 64 67
14 SATHYANARAYANAN 41/M 61 1.63 22.95 113 71 85 78 14 99 98 103 90 85 83 83 85 77 80 89
15 JEEVA 27/M 69 1.68 24.44 116 74 88 80 13 99 106 105 92 87 80 77 84 81 79
16 SHANMUGAM 60/M 67 1.62 25.52 124 86 99 67 12 98 88 93 89 79 74 77 75 69 70
17 SURESH BABU 45/M 74 1.67 26.53 113 71 85 73 12 99 97 94 96 87 79 83 79 74 70
18 MURUGAN 49/M 68 1.64 25.28 108 65 79 67 12 99 80 87 89 83 78 80 83 69 68 82
19 SUMATHI 20/F 49 1.54 20.66 110 67 81 70 14 99 92 97 95 90 87 81 79 75 75
20 MARIYAMMAL 55/F 52 1.53 22.21 117 71 86 74 13 98 91 93 87 83 88 79 81 72 74 85
21 VELU 45/M 63 1.6 24.6 127 77 94 81 12 99 105 102 91 86 83 77 80 83 87
22 JEYA 55/F 53 1.49 23.87 123 78 93 77 12 98 97 99 89 80 74 72 74 79 88
23 ANIL KUMAR 40/M 63 1.61 24.3 116 70 85 72 15 99 97 93 90 79 76 78 69 74 77
24 KARIKALAN 37/M 65 1.67 23.3 127 75 92 80 14 99 106 102 91 77 76 67 68 80 82
25 SYED ALI FATHIMA 42/F 50 1.56 20.54 123 69 87 71 12 99 110 106 98 90 85 81 79 85 83 95
26 VISALATCHI 57/F 54 1.52 23.37 109 63 78 67 12 98 87 88 79 85 78 71 72 76 79 87
27 NARASIMMAN 32/M 69 1.63 25.97 134 92 106 94 13 99 99 100 98 92 83 74 77 82 86
28 THIRUMOORTHY 28/M 67 1.69 23.45 120 82 95 81 12 99 106 102 101 94 87 70 79 80 77
29 IRSHAD AHMED 45/M 64 1.62 24.38 130 85 100 77 15 99 85 87 92 86 90 77 82 77 81 92
30 VASANTHA 50/F 55 1.53 23.49 113 70 84 68 13 98 79 79 81 84 88 79 80 76 79
POSTOPERATIVE  HR ( BEATS / MIN) 
GROUP 1  (NALBUPHINE  GROUP)
BASELINE VITALS
  
 
10 MINS 15 30 60 2HRS 3 4 6 8 10 10 MINS 15 30 60 2 HRS 3 4 6 8 10
126 121 119 117 109 112 114 117 123 85 83 79 76 70 68 73 70 73
132 127 121 124 115 117 119 123 125 87 86 80 79 73 71 70 81 73
125 128 120 118 114 110 106 112 115 126 79 83 77 74 74 72 68 73 69
130 133 137 130 123 117 109 111 109 81 81 83 79 81 77 68 74 65 79
133 131 126 124 120 125 119 113 120 85 80 71 72 77 76 72 77 82
126 125 122 121 117 121 117 115 124 129 84 84 75 74 75 78 71 70 81
140 137 134 129 121 117 114 117 118 92 90 83 81 79 81 77 78 76 82
129 129 132 126 117 113 117 116 115 81 86 84 82 84 82 83 85 75
129 131 125 117 110 111 123 119 123 87 83 81 70 73 77 69 70 86
119 117 116 110 106 106 109 113 116 121 77 80 74 69 67 73 70 69 75
127 129 132 127 123 117 121 122 121 79 81 76 79 70 68 74 73 70 77
123 122 114 109 110 112 117 125 120 81 77 69 66 65 68 77 76 81
115 114 124 115 113 111 115 124 123 74 69 73 69 71 69 70 72 71
119 123 130 122 117 115 111 112 117 130 80 68 79 73 74 73 72 72 77
126 129 126 119 112 117 119 117 115 82 80 72 75 69 73 68 67 75 83
123 119 124 125 118 121 124 121 126 84 73 84 80 67 77 74 81 82
117 121 113 117 113 117 120 117 123 80 72 79 75 70 68 73 80 80
120 127 125 114 110 113 110 115 114 129 82 77 76 69 73 75 79 85 84
115 110 119 120 106 109 106 112 117 77 68 71 77 78 79 81 82 87 86
119 123 127 123 112 109 107 115 115 131 78 87 82 73 71 77 80 77 80
131 134 132 127 115 117 113 113 114 87 84 81 75 76 81 73 71 82 85
130 126 119 112 107 105 109 112 120 88 79 74 68 70 70 71 70 69
126 123 120 119 113 112 117 121 127 85 75 70 73 74 72 72 68 68
137 140 145 129 115 111 114 120 132 96 80 82 79 80 78 81 72 79
130 132 130 120 123 119 109 118 130 139 92 81 81 80 82 83 80 73 81
121 125 128 123 119 121 122 118 124 130 84 82 74 72 70 80 84 81 87 85
145 139 137 129 123 117 117 114 113 100 91 84 74 68 73 79 85 82 83
132 130 131 119 110 118 113 115 119 87 79 80 75 73 74 80 82 84
141 136 127 118 107 109 110 116 119 120 108 94 82 79 80 75 81 79 88 79
130 132 124 119 113 107 106 112 125 79 81 73 70 68 70 75 77 81
POSTOPERATIVE SBP (mmHg) POSTOPERATIVE DBP (mmHg)
  
 
10 MINS 15 30 60 2 HRS 3 4 6 8 10 30 MINS 60 2 HRS 3 4 6 8 10 30MINS 60 2HRS 3
99 96 92 90 83 83 87 86 90 16 12 11 13 12 13 12 98 99 99 99
102 100 94 94 87 86 86 95 90 12 12 13 14 13 12 11 99 98 99 99
94 98 91 89 87 85 81 86 84 95 13 12 12 12 15 12 13 15 99 98 99 99
97 98 101 96 97 90 82 86 80 14 13 14 12 11 15 14 98 99 98 99
101 97 89 89 91 92 88 89 95 12 13 12 11 13 14 15 99 99 99 99
98 98 91 90 89 92 86 85 95 98 15 13 12 13 14 13 12 14 98 99 99 99
108 106 100 97 93 93 89 91 90 14 12 11 12 12 13 10 99 98 99 99
97 100 100 97 95 92 94 95 88 13 12 11 12 12 12 13 99 99 99 99
101 99 96 86 85 88 87 86 98 14 12 12 13 13 12 14 98 98 99 99
91 92 88 83 80 84 83 84 89 92 15 13 11 11 14 13 12 15 98 99 98 98
95 97 95 95 88 84 90 89 87 12 11 12 13 15 13 11 98 99 99 99
95 92 84 80 80 83 90 92 94 13 12 13 12 13 13 15 98 98 99 99
88 84 90 84 85 83 85 89 88 11 13 12 12 12 12 15 99 98 98 99
93 86 96 89 88 87 85 85 90 99 13 12 12 13 14 14 12 16 98 99 99 99
97 96 90 90 83 88 85 84 88 17 12 12 15 14 13 13 99 99 99 99
97 88 97 95 84 92 91 94 97 12 13 11 12 12 12 14 99 99 99 99
92 88 90 89 84 84 89 92 94 14 13 12 11 12 14 11 98 99 99 99
95 94 92 84 85 88 89 95 94 100 13 12 12 10 11 12 10 14 97 98 98 98
90 82 87 91 87 89 89 92 97 16 14 13 13 13 12 12 98 99 99 99
92 99 97 90 85 88 89 90 92 100 12 12 12 12 12 13 12 14 99 99 99 99
102 101 98 92 89 93 86 85 93 13 13 12 14 11 13 15 99 98 99 99
102 95 89 83 82 82 84 84 86 14 12 11 12 14 14 16 98 99 99 99
99 91 87 88 87 85 87 86 88 12 12 12 13 12 13 13 99 99 99 99
110 100 103 96 92 89 92 88 97 13 14 11 13 13 12 11 99 99 99 99
105 98 97 93 96 95 90 88 97 103 13 12 13 12 12 14 10 15 98 98 99 99
96 96 92 89 86 94 97 93 99 99 13 13 12 12 13 12 12 15 98 99 99 99
115 107 102 92 86 88 92 95 92 12 12 11 12 13 13 13 98 98 99 99
102 96 97 90 85 89 91 93 96 12 11 12 13 12 12 12 99 99 99 99
119 108 97 92 89 86 91 91 98 93 14 13 12 12 12 13 12 14 98 99 99 98
96 98 90 86 83 82 85 89 96 12 12 12 13 13 12 13 99 99 99 99
POSTOPERATIVE MAP (mmHg) RESPIRATORY RATE (/MIN) SpO2 (%)
  
 
SpO2
POSTOPERATIVE RESCUE 
ANALGESIA INITIATION TIME (HRS)
4 6 8 10 30 MINS 1 2 4 6 8 10
INJ DICLOFENAC 
INTRAMUSCULAR
HEADACHE DROWSINESS NAUSEA VOMITING
99 99 99 1 0 0 0 0 3 8
99 99 99 1 0 0 0 1 3 8
99 99 99 99 1 0 0 0 1 1 3 10 yes
98 99 98 2 1 1 0 0 3 8 yes
99 99 99 1 0 0 0 1 3 8
99 98 98 98 2 1 0 0 0 1 3 10
99 99 99 1 1 1 0 1 3 8
98 99 99 2 0 0 0 0 3 8 yes
99 99 99 2 1 1 0 1 3 8
99 99 99 99 1 0 0 0 0 2 4 10 yes
99 99 98 2 1 1 1 1 3 8
99 98 99 1 0 0 0 0 3 8
99 99 98 2 0 0 0 1 3 8
98 99 99 99 1 0 0 0 0 1 3 10
99 99 99 1 1 0 0 1 3 8
99 99 99 0 0 0 0 1 3 8 yes
99 99 99 1 0 0 0 0 3 8
99 99 99 99 1 0 0 0 1 1 3 10 yes
99 99 99 1 0 0 0 1 3 8
99 98 99 98 2 1 0 0 0 2 4 10
99 99 99 1 0 0 0 1 3 8
99 99 99 1 0 0 0 0 3 8 yes
99 99 98 2 0 0 0 1 3 8
99 99 99 2 1 1 1 2 3 8
99 99 99 99 1 0 0 0 0 2 4 10
99 99 99 99 2 0 0 0 0 2 4 10
99 99 99 1 1 0 0 1 3 8 yes
99 99 99 1 0 0 0 0 3 8
99 99 99 99 2 1 1 0 1 2 5 10
99 99 99 1 0 0 0 0 3 8
           COMPLICATIONS/ SIDE EFFECTS
VISUAL ANALOOG 
SCORE (HRS)
  
 
SERIAL
 NO 
NAME AGE/
SEX
WEIGHT
(KGS)
HEIGHT
(METERS)
BMI
(KG/M2)
SBP 
(mmHg)
DBP 
(mmHg)
MAP
 (mmHg)
HR /min RR / min SpO2 % 10 MINS 15 30 60 2 HRS 3 4 6 8 10
1 SARASWATHY 45/F 52 1.54 21.92 123 82 96 81 13 99 98 99 93 88 86 84 80 76 77
2 RAMAN 52/M 64 1.67 22.94 129 87 101 71 14 98 110 108 102 92 88 83 76 69 70
3 SARADHA 45/F 49 1.51 21.49 121 77 92 78 15 98 88 90 86 84 85 81 79 70 68 79
4 SUSEELA 35/F 51 1.56 20.95 117 76 90 67 13 99 93 97 89 86 86 87 77 78 74
5 ANTHONYSAMY40/M 69 1.7 23.87 115 73 87 91 12 99 92 88 82 83 81 77 83 79 83
6 CHANDRASEKAR34/M 63 1.68 22.32 124 83 97 84 13 99 93 90 84 81 80 76 78 81 84
7 GOKULRAJ 26/M 60 1.65 22.03 118 79 92 77 12 99 95 92 85 82 77 73 75 80 83
8 MAHALAKSHMI 57/F 50 1.46 23.45 109 66 80 65 14 98 87 89 80 80 79 76 77 83 86
9 JANAKI 44/F 57 1.65 20.93 115 70 85 75 13 99 89 93 81 82 81 78 77 71 79
10 EKAMBARAM 52/M 70 1.73 23.38 130 82 98 88 15 98 92 90 85 79 76 76 70 67 76
11 HARISH 23/M 58 1.57 23.53 116 71 86 78 16 99 90 91 87 83 79 75 73 70 68 80
12 SATHIYAVANI 54/F 56 1.48 25.56 112 69 83 87 12 98 87 89 84 79 80 81 85 88 81
13 SHENBAGAM 48/F 60 1.57 24.34 123 75 91 70 13 99 84 87 86 81 81 83 83 87 85
14 MUNUSAMY 38/M 65 1.67 23.3 125 79 94 83 12 99 98 92 88 84 80 82 80 86 90
15 KHALEEL RAHMAN59/M 72 1.72 24.33 132 87 102 66 12 98 107 103 101 94 89 90 88 83 81
16 PARVATHY 40/F 65 1.6 25.39 128 85 99 70 15 99 103 104 98 90 90 88 93 90 97
17 VIJAYAKUMAR 48/M 68 1.73 22.72 127 76 93 79 13 99 100 99 94 88 85 88 90 88 83
18 SANGEETHA 21/F 50 1.52 21.64 116 70 85 69 14 99 98 101 95 88 85 87 88 83 78
19 PAVITHRA 28/F 53 1.58 21.23 111 66 81 72 16 99 96 98 90 83 84 80 79 75 70 85
20 ELUMALAI 43/M 68 1.65 24.97 119 72 88 90 13 99 88 87 80 74 76 78 82 79 86
21 SUBRAMANI 49/M 69 1.74 22.79 118 74 89 84 14 98 85 89 83 77 78 76 70 71 76
22 HEMALATHA 50/F 57 1.55 23.72 124 78 93 77 12 98 96 100 93 87 85 83 77 70 74
23 RAVI 53/M 65 1.65 23.87 126 80 95 76 13 99 101 102 94 88 84 84 75 68 70 83
24 DIVYA 30/F 62 1.67 22.23 114 71 85 81 14 99 98 99 91 90 88 86 88 87 84
25 SATHIK BASHA 40/M 75 1.65 27.54 128 83 98 66 12 99 105 104 100 92 84 81 85 79 77
26 RADHIKA 43/F 54 1.59 21.35 115 68 84 78 14 99 86 84 79 73 70 72 76 81 81
27 GANDHIMATHY 47/F 58 1.55 24.14 108 65 79 82 13 99 79 83 76 71 69 70 79 85 88
28 MAHENDRAN 33/M 64 1.63 24.08 123 77 92 83 15 99 95 95 86 84 82 77 71 76 79
29 SELVI 35/F 57 1.58 22.83 114 69 84 70 12 99 102 103 95 89 87 83 78 87 87
30 CHARAN 29/M 62 1.66 22.49 122 80 94 74 13 99 95 96 88 88 89 86 85 83 88
GROUP 2 (TRAMADOL GROUP)
BASELINE VITALS POSTOPERATIVE HR (BEATS/MIN)
  
 
10 MINS 15 30 60 2 HRS 3 4 6 8 10 10 MINS 15 30 60 2 HRS 3 4 6 8 10
128 131 126 118 111 113 121 119 124 90 84 81 75 78 74 80 81 85
131 130 126 118 112 109 108 114 126 86 81 74 76 77 73 79 75 84
130 139 135 128 119 115 112 117 121 129 79 82 74 73 69 73 70 74 83 91
119 124 129 126 117 110 107 113 119 79 82 85 80 72 68 67 71 76
128 130 127 121 123 118 117 116 120 85 86 81 73 68 77 81 85 82
123 119 126 125 119 121 127 126 128 81 79 80 68 71 73 84 88 85
130 132 137 129 124 118 116 113 116 90 84 85 81 80 82 84 84 79
121 126 127 125 120 117 111 121 124 87 84 79 77 71 76 77 83 81
126 123 123 118 113 111 118 121 128 85 79 78 70 68 69 73 78 82
140 136 134 129 125 120 118 121 127 100 94 83 80 82 84 80 83 79
125 129 118 112 110 106 111 117 121 129 85 81 72 67 70 70 69 72 75 87
121 119 115 110 107 105 110 114 119 87 83 69 65 68 69 70 71 73
130 133 128 118 110 114 119 123 126 88 85 81 71 75 72 76 79 86
127 129 132 123 116 112 116 118 117 84 86 85 80 81 75 78 74 85
141 139 137 130 122 116 116 126 119 94 92 88 84 79 77 80 86 82
136 140 141 128 123 112 109 117 123 85 91 85 79 78 73 74 75 84
131 134 127 126 117 113 110 111 114 80 85 80 76 67 71 66 70 80
127 122 120 117 108 116 112 106 118 79 84 76 70 68 69 78 72 76
115 110 119 121 108 110 117 111 118 128 75 69 73 77 68 66 77 77 75 86
126 124 121 112 106 111 121 115 126 75 75 74 77 76 78 85 83 85
130 128 122 119 110 111 118 125 125 82 77 77 79 81 80 84 81 84
129 132 129 120 123 119 109 117 123 83 84 82 78 79 83 78 79 81
133 130 127 123 117 121 109 113 119 128 91 86 80 76 81 83 85 84 77 89
120 124 130 124 120 117 113 111 124 84 81 75 72 78 82 78 78 84
132 126 123 121 119 117 118 123 128 83 84 79 75 83 79 82 84 88
118 122 116 118 112 105 115 118 120 80 83 75 70 73 70 73 79 79
121 128 119 112 109 113 109 114 122 84 81 75 66 69 78 75 81 81
127 129 132 123 117 121 112 118 129 86 86 80 81 77 82 85 80 86
119 121 117 106 110 105 116 121 119 79 82 72 69 69 76 78 85 80
131 125 118 115 106 109 113 124 130 85 83 75 76 80 79 80 81 90
POSTOPERATIVE SBP (mmHg) POSTOPERATIVE DBP (mmHg)
  
 
10MINS 15 30 60 2 HRS 3 4 6 8 10 30 MINS 60 2 HRS 3 4 6 8 10 30MINS 60 2HRS 3
103 100 96 89 89 87 94 94 98 18 15 14 13 12 14 13 99 98 99 99
101 97 91 90 89 85 89 88 98 14 13 13 14 15 13 12 98 99 99 99
96 101 94 91 86 87 84 88 96 104 15 13 12 13 14 13 12 15 98 99 99 99
92 96 100 95 87 82 80 85 90 16 14 12 12 12 14 13 99 99 98 99
99 101 96 89 86 91 93 95 95 13 13 12 11 12 12 14 99 98 99 99
95 92 95 87 87 89 98 101 99 18 15 13 13 14 16 13 99 99 99 99
103 100 102 97 95 94 95 94 91 16 14 14 13 12 14 12 98 99 99 99
98 98 95 93 87 90 88 96 95 13 12 12 13 13 12 14 98 98 98 99
99 94 93 86 83 83 88 92 97 15 13 12 12 12 13 12 99 99 99 99
113 108 100 96 96 96 93 96 95 16 14 13 12 13 11 13 98 99 98 98
98 97 87 82 83 82 83 87 90 101 14 15 14 14 13 12 12 16 99 99 99 99
98 95 84 80 81 81 83 85 88 12 13 13 13 14 13 13 98 98 99 99
102 101 97 87 87 86 90 94 100 13 13 12 12 12 12 14 99 99 98 99
98 100 101 94 93 87 91 89 96 12 12 13 14 13 15 15 98 99 99 99
110 108 104 99 93 90 92 99 94 15 14 12 12 12 13 14 97 98 99 99
102 107 104 95 93 86 86 89 97 15 13 12 13 11 13 13 99 99 99 99
97 101 96 93 84 85 81 84 91 13 13 15 13 12 13 10 98 99 99 99
95 97 91 86 81 85 89 83 90 12 13 12 13 12 12 11 98 98 98 98
88 83 88 92 81 81 90 88 89 100 17 14 14 12 13 14 15 15 97 98 98 98
92 91 90 89 86 89 97 94 99 15 13 12 13 12 12 12 99 99 99 99
98 94 92 92 91 90 95 96 98 13 13 13 12 13 13 12 98 99 99 99
98 100 98 92 94 95 88 92 95 15 13 12 12 14 13 13 99 98 99 99
105 101 96 92 93 96 93 94 91 102 13 14 12 14 13 14 14 15 99 98 99 99
96 95 93 89 92 94 90 89 97 12 14 12 13 13 14 13 98 99 99 99
99 98 94 90 95 92 94 97 101 16 15 13 12 13 14 12 99 99 99 99
93 96 89 86 86 82 87 92 93 14 12 14 13 14 13 12 98 99 99 99
96 97 90 81 82 90 86 92 95 14 12 11 12 12 14 13 99 98 99 99
100 100 97 95 90 95 94 93 100 13 11 12 14 13 12 14 98 99 99 99
92 95 87 81 83 86 91 97 93 15 13 12 11 10 12 13 99 98 99 98
100 97 89 89 89 89 91 95 103 13 12 13 13 12 13 11 98 98 98 98
RESPIRATORY RATE (/MIN) SpO2 (%)POSTOPERATIVE MAP (mmHg)
  
 
 
SpO2
VISUAL
 ANALOG 
SCORE (HRS)
POSTOPERATIVE 
RESCUE ANALGESIA
 INITIATION TIME (HRS) 
COMPLICATIONS/
SIDE EFFECTS
4 6 8 10 30 MINS 1 2 4 6 8 10
INJ DICLOFENAC
 INTRAMUSCULAR
HEADACHE DROWSINESS NAUSEA VOMITTING
99 99 99 1 0 0 0 1 3 8 YES
99 99 98 2 1 1 1 2 4 8
99 99 99 99 2 0 0 0 1 2 4 10 YES
99 99 99 2 1 0 0 1 3 8
99 99 99 1 0 0 0 2 4 8
99 99 99 3 1 1 1 1 3 8
99 99 99 1 0 0 0 1 3 8 YES YES
99 99 99 2 0 0 0 2 4 8
99 99 99 2 1 1 1 1 3 8
98 98 98 2 0 0 0 0 3 8
99 99 99 99 2 0 0 0 1 2 4 10 YES
99 99 99 2 0 0 0 1 3 8
99 99 99 2 1 1 2 2 3 8
99 99 98 1 0 0 0 0 4 8 YES
99 99 99 2 1 0 0 1 3 8 YES
99 99 99 2 1 1 1 1 3 8
99 99 99 1 0 0 0 0 3 8 YES
98 98 98 2 1 0 0 1 3 8
98 99 99 99 1 0 0 1 1 2 3 10
99 99 99 3 1 1 2 2 3 8 YES
99 99 99 1 0 0 0 1 4 8 YES
99 99 99 2 1 1 1 0 3 8
99 99 99 99 1 0 0 0 1 2 4 10
99 99 99 2 0 0 0 0 3 8 YES
99 98 98 2 0 0 1 2 4 8
99 99 99 1 0 0 0 1 3 8
99 99 99 2 1 1 1 1 3 8 YES YES
99 99 99 1 0 0 0 1 3 8
99 99 99 2 1 1 0 0 4 8
98 98 98 1 0 0 0 1 3 8
